Wednesday, January 4, 2023

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies

 Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA application will request approval for Adimune to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023, with a second study also planned for type 1 diabetes. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the therapeutics business unit at multinational pharmaceutical company Schering AG, will serve as chairman of the board and CEO of Adimune. “My vision for Adimune is to advance our program and effectively demonstrate that ADI technology is designed to restore immune health in patients with autoimmune diseases such as psoriasis and type 1 diabetes,” said Dr. Kapp. “We believe 2023 will be a pivotal year for us as we prepare and implement CTA approved clinical human trials featuring our drug candidate, ADI-100, which we believe to be extremely promising.”

To view the full press release, visit https://ibn.fm/kqoRD

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html